<DOC>
	<DOC>NCT01128452</DOC>
	<brief_summary>This study is a 4-week, randomized, double-blind, parallel-group, placebo-controlled monotherapy study in patients with treatment-resistant major depression. After confirmation of treatment-resistance in a prospective treatment period with citalopram, each patient will be treated with either EVT 101 once daily or placebo for 28 consecutive days.</brief_summary>
	<brief_title>Safety and Efficacy of EVT 101 in Treatment-Resistant Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
	<criteria>Major Depressive Disorder Current episode of major depression that has not benefited from at least 1 but no more than 3 adequate treatment regimens Has as score of &gt;/= 18 on the HamD17 Pregnant or breastfeeding women Evidence of agerelated cognitive decline or mild dementia At imminent risk of committing suicide Has with the exception of major depression, a serious medical or neurological illness, including seizure disorder, stroke, dementia, or Parkinson disease Has an established diagnosis of bipolar disorder, hypomania, schizoaffective disorder, major depression with psychotic features or schizophrenia Has had a substance or alcohol abuse or dependence disorder (except nicotine and caffeine) in the 1 year before screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Treatment-Resistant Depression</keyword>
</DOC>